U.S. markets closed
  • S&P Futures

    3,848.50
    +0.25 (+0.01%)
     
  • Dow Futures

    31,014.00
    +1.00 (+0.00%)
     
  • Nasdaq Futures

    11,888.50
    +8.25 (+0.07%)
     
  • Russell 2000 Futures

    1,730.00
    +1.40 (+0.08%)
     
  • Crude Oil

    98.29
    -0.24 (-0.24%)
     
  • Gold

    1,739.90
    +3.40 (+0.20%)
     
  • Silver

    19.17
    +0.02 (+0.08%)
     
  • EUR/USD

    1.0192
    +0.0007 (+0.07%)
     
  • 10-Yr Bond

    2.9130
    +0.1040 (+3.70%)
     
  • Vix

    26.73
    -0.81 (-2.94%)
     
  • GBP/USD

    1.1931
    +0.0009 (+0.08%)
     
  • USD/JPY

    135.7800
    -0.1350 (-0.10%)
     
  • BTC-USD

    20,535.96
    +243.66 (+1.20%)
     
  • CMC Crypto 200

    446.87
    +11.34 (+2.60%)
     
  • FTSE 100

    7,107.77
    +82.30 (+1.17%)
     
  • Nikkei 225

    26,259.91
    +152.26 (+0.58%)
     

Cogent Biosciences to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass. and BOULDER, Colo., Nov. 22, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins, Chief Executive Officer and President will participate in a fireside chat and one-on-one investor meetings during the Piper Sandler 33rd Annual Healthcare Conference, taking place virtually November 29December 2, 2021.

(PRNewsfoto/Cogent Biosciences, Inc.)
(PRNewsfoto/Cogent Biosciences, Inc.)

The pre-recorded fireside chat will be available to conference attendees starting at 10:00 a.m. ET today and will remain available through the end of the conference on Thursday, December 2. Access to the recording will be available under the "Events" tab on the investor relations section of the Cogent Biosciences website at: https://investors.cogentbio.com/events.

About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the newly formed Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases. Cogent Biosciences is based in Cambridge, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: Twitter and LinkedIn. Information that may be important to investors will be routinely posted on our website and Twitter.

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/cogent-biosciences-to-present-at-piper-sandler-33rd-annual-virtual-healthcare-conference-301429300.html

SOURCE Cogent Biosciences, Inc.